Probity Medical Research

Recent papers from Probity Medical Research

1. Sustained AD Control After Abrocitinib: Dose Effects and Biomarker InsightsSKIN The Journal of Cutaneous Medicine · 2026
2. Real-World Effectiveness of Risankizumab for Moderate-to-Severe Plaque Psoriasis by Sub-populations: Interim Analysis from VALUE at 37 MonthsDermatology and Therapy · 2026
3. Povorcitinib for nonsegmental vitiligo: two randomized, controlled, phase 3 STOP-V trialsNature Medicine · 2026
4. Lebrikizumab Provides Stable and Deep Long-Term Response with No/Minimal Fluctuations up to 3 Years in Patients with Moderate-to-Severe Atopic DermatitisDermatology and Therapy · 2026
5. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trialsThe Lancet · 2018
6. Does Baseline Severity of Atopic Dermatitis Impact the Long-Term Efficacy of Abrocitinib? Post-hoc Analysis of Two Randomized TrialsDermatology and Therapy · 2026
7. Canadian Expert Consensus Recommendations on the Use of Photodynamic Therapy in Actinic KeratosisDermatology and Therapy · 2026
8. Sonelokimab, a novel IL-17A- and IL-17F-inhibiting nanobody for the treatment of moderate-to-severe hidradenitis suppurativa: a global, randomized, double-blind, placebo-controlled phase 2 clinical trial (MIRA)Journal of the American Academy of Dermatology · 2026
9. Development of a Conceptual Disease Model of Atopic Dermatitis Using Data from the Phase 3 ARCADIA 1 TrialDermatology and Therapy · 2026
10. Dupilumab-Associated Facial and Neck Erythema: An Updated Systematic Review of Management StrategiesJournal of Cutaneous Medicine and Surgery · 2026
11. Real-World Evidence of Upadacitinib in Atopic Dermatitis after Inadequate Response or Intolerance to Dupilumab: The CAN UpTIMISE StudyDermatology and Therapy · 2026
12. Safety of Icotrokinra Through 1 Year for the Treatment of Moderate-to-Severe Plaque Psoriasis and Psoriasis Affecting High-Impact Sites: Pooled Results Across the ICONIC-LEAD, ICONIC-TOTAL, and ICONIC-ADVANCE 1 and 2 Phase 3 TrialsDermatology and Therapy · 2026
13. Upadacitinib for Severe Alopecia Areata in Adults and AdolescentsJAMA Dermatology · 2026
14. Simulating real-world abrocitinib use in atopic dermatitis: results from JADE REALJournal of Dermatological Treatment · 2026
15. Prevalence of Regulatory Safety Risk Factors Among Adolescents and Adults With Atopic Dermatitis Receiving Advanced Systemic Therapies: An International Real‐World StudyInternational Journal of Dermatology · 2026
16. Janus kinase inhibitors combined with 308‐nm excimer laser for vitiligo: A systematic reviewJournal of the European Academy of Dermatology and Venereology · 2026
17. Dual Targeted Therapy as a Treatment Strategy for Refractory Psoriatic Arthritis: Real‐World Effectiveness and Safety From a Prospective CohortACR Open Rheumatology · 2026
18. Achieving Minimal Disease Activity in Atopic Dermatitis Is Associated with Fewer Flares, Reduced Healthcare Resource Utilization, and Improved Disease Control: Analysis from the Real-World MEASURE-AD StudyDermatology and Therapy · 2026
19. Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trialsNature Medicine · 2026
20. Delgocitinib cream formulation demonstrates a dose-dependent response in adults with mild to severe atopic dermatitis: results from an 8-week randomised Phase IIb trialBritish Journal of Dermatology · 2026